GLOMAR from SEC Regarding Investigations into Emergent Bio Solutions CEO’s Stock Sales

The U.S. Securities and Exchange Commission stated that it could not confirm or deny the existence of records responsive to American Oversight’s request for documents relevant to any agency investigations into Emergent BioSolutions CEO Robert Kramer’s sale of his company’s stock shortly before its stock prices plummeted because of the contamination of Johnson & Johnson Covid-19 vaccines.